Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 16/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10311215 | 0.87 | NOTUM (0.52) | NOTUMAR | |
| SCHEMBL2625786 | 0.77 | NOTUM (0.59) | NOTUMAR | |
| SCHEMBL12656140 | 0.77 | NOTUM (0.51) | NOTUMHRH3 | |
| SCHEMBL10311202 | 0.76 | NOTUM (0.51) | NOTUMAR | |
| SCHEMBL13228227 | 0.76 | NOTUM (0.53) | NOTUMHRH3 | |
| SCHEMBL26890101 | 0.76 | DRD2 (0.41) | HRH3 | |
| SCHEMBL2271564 | 0.76 | HRH3 (0.41) | HRH3 | |
| SCHEMBL21859836 | 0.75 | DRD2 (0.41) | NOTUMHRH3 | |
| Bromide SCHEMBL6844504 | 0.75 | HRH3 (0.40) | HRH3 | |
| SCHEMBL10130560 | 0.74 | NOTUM (0.49) | NOTUMAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178752-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-12 | — | — | US | disclosed |
| US-8163720-B2 | Pyrrolidinyl phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, TRPA1 | NOTUM 2423/4885AR 3992/4885HRH3 1102/4885 |
| US-20120178752-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | NOTUM 3757/4885AR 3842/4885HRH3 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.